Skip to content
Review Open access

Targeting Dengue Viral Proteins with Eco-Friendly Nanotechnology: A Promising Path for Antiviral Research

Sep 2026 · Viruses · Vol 18 · 0 citations · 96 references
Medicine

TL;DR

The findings discussed in this review underscore the promise of eco-friendly nanotechnology as a sustainable and effective platform for developing next-generation antiviral therapies against dengue virus.

Abstract

Dengue virus (DENV), a mosquito-borne pathogen belonging to the Flaviviridae family, continues to be a major global public health concern, causing millions of infections annually across tropical and subtropical regions. The virus encodes both structural and non-structural proteins that play critical roles in its replication, assembly, and immune evasion. Despite substantial research progress, there is still no specific antiviral drug available, and current treatment remains primarily supportive. This review highlights the significance of DENV structural proteins (C, prM/M, and E) and non-structural proteins (NS1–NS5) as potential molecular targets for antiviral interventions. Green-synthesized silver, gold, and iron oxide nanoparticles have demonstrated strong inhibitory activity against DENV by targeting key viral proteins such as the envelope (E), NS3 protease/helicase, and NS5 RNA-dependent RNA polymerase. These nanoparticles interfere with viral entry, replication, and protein synthesis while exhibiting high biocompatibility and minimal cytotoxicity. Collectively, the findings discussed in this review underscore the promise of eco-friendly nanotechnology as a sustainable and effective platform for developing next-generation antiviral therapies against dengue virus.

Read PDF

Similar papers

Review Open access Aug 2026

Dengue Virus Molecular Targets and Antiviral Drug Development: Advances, Challenges and Therapeutic Perspectives

This narrative review critically analyses the principal molecular targets of DENV, including structural proteins (C, prM/M and E), nonstructural proteins (NS1–NS5) and host factors, with emphasis on the development of small‐molecule antivirals and an evaluation of their progress in pre‐clinical and clinical studies.

Aryane Lucia da Silva Aguiar De Oliveira, José Arion da Silva Moura, Pedro César de Souza et al. · 0 citations
Review Sep 2026

Structural biology of the dengue virus NS2B-NS3 protease as a target for antiviral drug development.

A comprehensive overview of the detailed structural information of the viral protease (NS2B/NS3) enzyme with the mechanistic role of this enzyme, and various inhibitors related to the NS2B/NS3 protease are highlighted.

Rahit Paul, Deeti Jyothi, Maitreyee Mukherjee et al. · 0 citations
Sep 2026

Unveiling the antiviral mechanism of A4S7: a synthetic antimicrobial peptide targeting dengue and other mosquito-borne enveloped virus infections.

Dengue virus (DENV), an enveloped mosquito-borne flavivirus, is the causative agent of dengue and prevalent in tropical and subtropical regions. Severe cases can progress to dengue hemorrhagic fever or shock syndrome, posing significant public health challenges. In the absence of specific antiviral drugs, antimicrobial...

Ting-Chun Lin, Jeng-Wei Lu, Chia-Hsin Liu et al. · 0 citations
Review Open access Aug 2026

Target-Based Antiviral Drug Development Against Human Respiratory Viruses

This review examines the principles and applications of target-based antiviral drug development against human respiratory viruses, emphasizing the identification and exploitation of conserved viral and host targets.

S. K. Samrat, Gaurie Srivastava, Ran Zhang et al. · 0 citations
Review Open access Sep 2026

Zika Virus Pathogenesis and Therapeutic Prospects: Molecular Mechanisms, Neurological Implications, and Emerging Antiviral Scaffolds

A comprehensive overview of ZIKV pathogenesis, transmission routes, and molecular mechanisms underlying host–virus interactions is provided, with emphasis on structural and functional insights into key viral enzymes NS2B–NS3 protease and NS5 RNA-dependent RNA polymerase which serve as pivotal antiviral drug targets.

Arvind Kumar, Harpreet Singh, Sagar Varshney et al. · 0 citations
Review Open access Sep 2026

Nanotechnology-Enabled Therapeutics for Global Viral Diseases: From COVID-19 to Emerging Viral Infections

This review aims at assessing the latest advancements in the field of nanotechnology in terms of developing therapeutic interventions in viral diseases, especially COVID-19 and other emerging viral infections.

Abhishek Kumar, Anamika Gaurishankar Parihar · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.